ABBV slips after FDA approval pop
The stock is giving back gains through likely profit-taking after the FDA approval of its Parkinson's drug JUVMO, a positive catalyst that had already lifted the shares, while the broader market also trades lower.
Sources: https://finance.yahoo.com/healthcare/articles/fda-nod-juvmo-parkinson-drug-051117671.html, https://finance.yahoo.com/healthcare/articles
Sources
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works